P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma
Noopur Raje,Edward A. Faber,Paul G. Richardson,Gary J. Schiller,Raymond J. Hohl,Adam D. Cohen,Andres Forero,Susan P. Carpenter,Damien M. Cronier,Christopher Kaiser,James E. Wooldridge,Kenneth C. Anderson +11 more
TL;DR: A 100 mg dose of tabalumab in combination with bortezomib was well tolerated; 22 patients achieved a PR or better despite prior bortzomib and/or IMiD therapy, supporting the hypothesis that a higher dose oftabalumAB should be evaluated.
Journal ArticleDOI
Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa.
Pontiano Kaleebu,Harr Freeya Njai,Lei Wang,Norman G. Jones,Isaac Ssewanyana,Paul G. Richardson,Kenneth Kintu,Lynda Emel,Philippa Musoke,Philippa Musoke,Mary Glenn Fowler,San San Ou,J. Brooks Jackson,Laura Guay,Philip Andrew,Lynn Baglyos,Huyen Cao +16 more
TL;DR: HIV-1–exposed infants are capable of generating low levels of cellular immune responses to ALVAC vaccine, similar to responses seen in adults.
Journal ArticleDOI
Molecular dynamics of targeting CD38 in multiple myeloma
Fabio Malavasi,Angelo Corso Faini,Fabio Morandi,Barbara Castella,Danny Incarnato,Salvatore Oliviero,Alberto L. Horenstein,Massimo Massaia,Niels W.C.J. van de Donk,Paul G. Richardson +9 more
TL;DR: In this paper, microvesicles from antibody-exposed cells were analysed for differential gene and microRNA expression, and for phenotypic characterisation of MM cells and subsequent events when anti-CD38 is targeted by therapeutic antibodies.
Journal ArticleDOI
Pomalidomide (POM), bortezomib, and low‐dose dexamethasone (PVd) vs bortezomib and low-dose dexamethasone (Vd) in lenalidomide (LEN)-exposed patients (pts) with relapsed or refractory multiple myeloma (RRMM): Phase 3 OPTIMISMM trial.
Paul G. Richardson,Albert Oriol Rocafiguera,Meral Beksac,Anna Marina Liberati,Monica Galli,Fredrik Schjesvold,Jindriska Lindsay,Katja Weisel,Darell White,Thierry Facon,Jesús F. San-Miguel,Kazutaka Sunami,Peter O'Gorman,Pieter Sonneveld,Xin Yu,Thomas Doerr,Amine Bensmaine,Mohamed H. Zaki,Kenneth C. Anderson,Meletios A. Dimopoulos +19 more
TL;DR: POM + DEX is indicated as a standard-of-care treatment in RRMM with demonstrated synergistic anti-myeloma activity with dexamethasone (DEX) and proteasome inhibitors (PIs).
Journal ArticleDOI
A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results.
Andrzej Jakubowiak,Todd M. Zimmerman,Melissa Alsina,Paul G. Richardson,Jonathan L. Kaufman,Tara Kendall,Christine Brozo,A. McAllister,C. Leister,Teru Hideshima,Peter Sportelli,L. Gardner,Robert Birch,I. C. Henderson,Kathy Giusti,Kenneth C. Anderson +15 more
TL;DR: This phase 1 study aimed to determine MTD and activity of Peri + Rev + Dex, in patients with relapsed/refractory MM, with no unexpected toxicities and clinical activity has been noted within the first 2 cohorts.